These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38498313)

  • 1. Clinical outcomes among initial survivors of cryptogenic new-onset refractory status epilepsy (NORSE).
    Costello DJ; Matthews E; Aurangzeb S; Doran E; Stack J; Wesselingh R; Dugan P; Choi H; Depondt C; Devinsky O; Doherty C; Kwan P; Monif M; O'Brien TJ; Sen A; Gaspard N
    Epilepsia; 2024 Jun; 65(6):1581-1588. PubMed ID: 38498313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical presentation of new onset refractory status epilepticus in children (the pSERG cohort).
    Sculier C; Barcia Aguilar C; Gaspard N; Gaínza-Lein M; Sánchez Fernández I; Amengual-Gual M; Anderson A; Arya R; Burrows BT; Brenton JN; Carpenter JL; Chapman KE; Clark J; Gaillard WD; Glauser TA; Goldstein JL; Goodkin HP; Gorman M; Lai YC; McDonough TL; Mikati MA; Nayak A; Peariso K; Riviello J; Rusie A; Sperberg K; Stredny CM; Tasker RC; Tchapyjnikov D; Vasquez A; Wainwright MS; Wilfong AA; Williams K; Loddenkemper T;
    Epilepsia; 2021 Jul; 62(7):1629-1642. PubMed ID: 34091885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cryptogenic New Onset Refractory Status Epilepticus (NORSE) in adults-Infectious or not?
    Costello DJ; Kilbride RD; Cole AJ
    J Neurol Sci; 2009 Feb; 277(1-2):26-31. PubMed ID: 19013586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropathology of New-Onset Refractory Status Epilepticus (NORSE).
    Hanin A; Cespedes J; Huttner A; Strelnikov D; Gopaul M; DiStasio M; Vezzani A; Hirsch LJ; Aronica E
    J Neurol; 2023 Aug; 270(8):3688-3702. PubMed ID: 37079033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New onset refractory status epilepticus: State of the art.
    Périn B; Szurhaj W
    Rev Neurol (Paris); 2022; 178(1-2):74-83. PubMed ID: 35031143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective cohort study of new-onset refractory status epilepticus (NORSE): clinical features, timing of immunotherapy and outcomes.
    Werbaneth K; Mausolf M; Seliger J; Le S
    Epileptic Disord; 2022 Oct; 24(5):867-876. PubMed ID: 35892128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions.
    Hirsch LJ; Gaspard N; van Baalen A; Nabbout R; Demeret S; Loddenkemper T; Navarro V; Specchio N; Lagae L; Rossetti AO; Hocker S; Gofton TE; Abend NS; Gilmore EJ; Hahn C; Khosravani H; Rosenow F; Trinka E
    Epilepsia; 2018 Apr; 59(4):739-744. PubMed ID: 29399791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to FIRE NORSE: A single acronym for a heterogeneous presentation. Further information from a case series and discussion of the literature.
    Alaskar AM; Aljohani MA; Dionisio S; Asiry MA; Alqadi K
    J Neuroimmunol; 2024 Mar; 388():578298. PubMed ID: 38330780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of subsequent extra-temporal involvement in cryptogenic new onset refractory status epilepticus (NORSE) initially diagnosed with limbic encephalitis.
    Choi JY; Kim EJ; Moon SY; Kim TJ; Huh K
    Epilepsy Res; 2019 Dec; 158():106215. PubMed ID: 31669912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unraveling the enigma of new-onset refractory status epilepticus: a systematic review of aetiologies.
    Lattanzi S; Leitinger M; Rocchi C; Salvemini S; Matricardi S; Brigo F; Meletti S; Trinka E
    Eur J Neurol; 2022 Feb; 29(2):626-647. PubMed ID: 34661330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective study of 92 children with new-onset refractory status epilepticus.
    Wu J; Lan X; Yan L; Hu Y; Hong S; Jiang L; Chen J
    Epilepsy Behav; 2021 Dec; 125():108413. PubMed ID: 34794014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of patients with new onset refractory status epilepticus preceded by fever (febrile infection-related epilepsy syndrome) versus without prior fever: An interim analysis.
    Jimenez AD; Gopaul M; Asbell H; Aydemir S; Basha MM; Batra A; Damien C; Day GS; Eka O; Eschbach K; Fatima S; Fields MC; Foreman B; Gerard EE; Gofton TE; Haider HA; Hantus ST; Hocker S; Jongeling A; Kalkach Aparicio M; Kandula P; Kang P; Kazazian K; Kellogg MA; Kim M; Lee JW; Marcuse LV; McGraw CM; Mohamed W; Orozco J; Pimentel C; Punia V; Ramirez AM; Steriade C; Struck AF; Taraschenko O; Treister AK; Yoo JY; Zafar S; Zhou DJ; Zutshi D; Gaspard N; Hirsch LJ; Hanin A
    Epilepsia; 2024 Jun; 65(6):e87-e96. PubMed ID: 38625055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A practical approach to in-hospital management of new-onset refractory status epilepticus/febrile infection related epilepsy syndrome.
    Sheikh Z; Hirsch LJ
    Front Neurol; 2023; 14():1150496. PubMed ID: 37251223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New-onset super-refractory status epilepticus: A case series of 26 patients.
    Matthews E; Alkhachroum A; Massad N; Letchinger R; Doyle K; Claassen J; Thakur KT
    Neurology; 2020 Oct; 95(16):e2280-e2285. PubMed ID: 32943479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line immunotherapy in new onset refractory status epilepticus.
    Hanin A; Muscal E; Hirsch LJ
    Epilepsia; 2024 May; 65(5):1203-1223. PubMed ID: 38430119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): State of the art and perspectives.
    Gaspard N; Hirsch LJ; Sculier C; Loddenkemper T; van Baalen A; Lancrenon J; Emmery M; Specchio N; Farias-Moeller R; Wong N; Nabbout R
    Epilepsia; 2018 Apr; 59(4):745-752. PubMed ID: 29476535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The seasonality of new-onset refractory status epilepticus (NORSE).
    Gopaul MT; Hanin A; Cespedes J; Pulluru Y; Kazazian K; van Baalen A; Gofton TE; Gaspard N; Hirsch LJ
    Epilepsia; 2023 Jun; 64(6):e112-e117. PubMed ID: 37013696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cryptogenic new-onset refractory status epilepticus responded to anti-interleukin-6 treatment.
    Wadayama T; Shimizu M; Yata T; Ishikura T; Kajiyama Y; Hirozawa D; Okuno T; Mochizuki H
    J Neuroimmunol; 2022 Feb; 363():577789. PubMed ID: 34973472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes after NORSE: Treatment with vagus nerve stimulation.
    Espino PH; Burneo JG; Moscol G; Gofton T; MacDougall K; Suller Marti A
    Epilepsia Open; 2022 Dec; 7(4):822-828. PubMed ID: 36177520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New onset refractory status epilepticus (NORSE).
    Sculier C; Gaspard N
    Seizure; 2019 May; 68():72-78. PubMed ID: 30482654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.